Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in resectable head and neck cancer
NCT07094685Phase 2Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Nov 2025
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Michigan Rogel Cancer Center. Started Nov 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07094685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07094685.